Searchable abstracts of presentations at key conferences in endocrinology

ea0009p121 | Endocrine tumours and neoplasia | BES2005

Absence of specific effect of DHEA-S deficiency on mood and quality of life in Addisons disease

Adma P , Heald A , Kane J , Gibson C , Davis J , Buckler H , Fowler H

Clinic based studies have shown that patients with Addison's disease have relatively high rates of depression and anxiety symptoms compared with population-based reference samples. Addison's disease results in deficiency of dehydroepiandrosterone (DHEA) and DHEA-sulphate in addition to glucocorticoids and mineralocorticoids. DHEA is thought to have beneficial effects on energy level and mood, independent of circulating testosterone levels. Thus there may be a direct link betwe...

ea0009p119 | Endocrine tumours and neoplasia | BES2005

Comparison of long term psychological health in patients with treated Pituitary Cushing's and Nelson's syndrome vs. Adrenal Cushing's

Ghosh S , Heald A , Gibson C , Bray S , Anderson S , O'Driscoll K , Davis J , Buckler H , Fowler H

IntroductionWe have previously shown that patients with pituitary Cushing's have impaired quality of life vs. other pituitary tumour groups. Whether this is related to direct neural effects of excess ACTH or cortisol is uncertain. In order to address this, we compared patients who had undergone definitive treatment for pituitary vs adrenal Cushings.DesignWe assessed 14 patients with biochemically cured pituit...

ea0005p192 | Neuroendocrinology and Behaviour | BES2003

Audit of quality of life in individuals who have undergone treatment for pituitary tumours over the past ten years at a single neurosurgical centre

Fowler H , Ghosh S , Buckler H , Heald A

Adults with brain tumours experience changes in multiple aspects of quality of life and this is associated with their medical condition and its treatment. There is some evidence to suggest that the mode of treatment is also a significant factor in the development of affective symptomatology. The primary aim is to explore within our cohort of patients treated for pituitary tumours, whether there are significant differences in multiple domains of quality of life and the severity...

ea0005p209 | Reproduction | BES2003

Immunopurification of gonadotrophin surge-attenuating factor (GnSAF) bioactivity

Sorsa-Leslie T , Harris W , Mason H , Fowler P

Objective We aimed to immunopurify GnSAF, using antibodies with demonstrated GnSAF bioactivity-blocking/binding activity, in order to confirm 2 new candidate amino acid sequences for human ovarian GnSAF (Fowler et al. Mol Human Reprod 2002;8:823-832).Methods Rat antiserum, raised against a 60-70 kDa band of partially purified GnSAF, was immobilised on anti-rat IgG Dynabeads. In addition, a human antibody, derived from a phage display antibody library a...

ea0003p231 | Reproduction | BES2002

Engineering of single chain antibodies selected from a phage display library into human IgGs that recognise gonadotrophin surge-attenuating factor (GnSAF) bioactivity

Sorsa-Leslie T , Harris W , Mason H , Fowler P

Introduction. We have previously used a synthetic phage display library to derive single chain (ScAbs) antibodies which bind GnSAF bioactivity in-vitro. However, recovery of GnSAF using the ScAbs, which tended to aggregate and become unstable, was limited. We have therefore engineered these ScAbs into full-length human IgG forms.Methods. CDR regions from soluble expression plasmids for two different GnSAF-recognising ScAbs were amplified by PCR. Two uni...